合约开发和生产组织 (CDMO) 市场规模、份额和成长分析（按服务、最终用户和地区划分）- 产业预测 (2026-2033)

全球医药合约开发和生产组织 (CDMO) 市场规模预计在 2024 年达到 1501.2 亿美元，从 2025 年的 1600.6 亿美元增长到 2033 年的 2672.9 亿美元，在预测期（2026-2033 年）复合年增长率为 6. 62%。

医药合约开发与生产市场透过向製药公司提供包括成品製剂和活性药物成分生产以及药物研发在内的多种服务，实现了显着成长。推动这一成长的因素包括先进技术的应用、专利到期、研发投入的增加以及对学名药和生物製药需求的成长。此外，人们对细胞和基因疗法、个人化医疗、高效药物成分以及抗体药物复合体（ADC）的兴趣日益浓厚，也进一步推动了市场需求。然而，序列化需求和合格人员短缺等挑战可能会阻碍市场成长。总体而言，市场格局仍在不断演变，反映出该行业已做好充分准备，以应对新的治疗需求和技术进步。

推动全球医药合约开发与生产市场发展的因素

全球药品合约研发生产市场正蓬勃发展，这主要得益于外包带来的诸多优势，尤其是成本和时间效率的提升。该行业的公司正大力投资基础设施、人力资源和技术能力的提升，力求在外包收入中占据更大的份额。透过策略性地提高营运效率和资源配置，这些公司能够更好地满足客户需求，并实现更精简、更具成本效益的生产流程。因此，在对专业外部合作伙伴日益增长的依赖下，药品研发生产市场持续扩张。

全球药品合约开发和生产市场阻碍因素

对流程理解的不足会导致产品线缺陷，从而削弱消费者信心，并危及研发商、製造商和经销商之间的关係。这种不确定性威胁到全球医药合约研发生产市场的信任度，因为相关人员会因为担心品质保证而不愿合作。这反过来又会增加产品召回和负面宣传的风险，最终影响产业的盈利和永续性。因此，加深对流程的理解对于降低这些风险、创造更稳健可靠的市场环境至关重要。

全球医药合约开发与生产市场趋势

全球药品合约开发和生产市场正呈现出显着的发展趋势，这主要得益于对特异性癌症治疗需求的不断增长以及药物开发技术的进步。随着癌症发生率的上升，人们的关注点已明显转向开发安全、有效且高效的新型化学实体（NCE），这些药物具有更高的选择性和更优的给药方案。对标靶治疗的日益关注促使製药公司积极利用合约生产服务作为高效的生产解决方案，从而提升其将创新药物快速推向市场的能力。因此，市场正在不断发展以满足这些新兴需求，并专注于扩充性、柔软性和严格的品质合规性。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术分析
• 监管分析
• 案例研究

全球医药合约开发和生产组织（CDMO）市场规模（按服务类型和复合年增长率划分）（2026-2033 年）

• 製药生产服务
  • 原料药製造服务
  • FDF製造服务
• 药物开发服务
• 生物製药生产服务
  • 原料药製造服务
  • FDF製造服务
• 包装服务

全球医药合约开发和生产组织（CDMO）市场规模（按最终用户和复合年增长率划分）（2026-2033 年）

• 大型製药公司
• 中小型製药公司
• 学名药生产商
• 其他的

全球合约开发生产组织（CDMO）市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Cambrex Corporation
• Samsung Biologics Co., Ltd.
• Siegfried Holdings AG
• FUJIFILM Diosynth Biotechnologies
• Aenova Group
• Wuxi Biologics, Inc.
• Aurobindo Pharma, Ltd.
• Vetter Pharma International GmbH
• Thermo Fisher Scientific, Inc.
• Catalent, Inc
• Recipharm AB
• Almac Group
• Lonza Group Ltd.
• Piramal Enterprises Limited
• Fabbrica Italiana Sintetici SpA
• Fareva SA
• CH Boehringer Sohn AG & Co. KG.
• Jubilant Pharmova Limited
• Curia Global, Inc.
• Delpharm Holdings

结论与建议

Global Pharmaceutical Contract Development and Manufacturing Market size was valued at USD 150.12 Billion in 2024 and is poised to grow from USD 160.06 Billion in 2025 to USD 267.29 Billion by 2033, growing at a CAGR of 6.62% during the forecast period (2026-2033).

The market for pharmaceutical contract development and manufacturing is experiencing notable growth as firms offer diverse services to pharmaceutical clients, including the production of final dosage forms, active pharmaceutical ingredients, and drug research. Factors driving this expansion include the adoption of advanced technologies, patent expirations, increased R&D investment, and heightened demand for generic medications and biologics. Additionally, the rising interest in cell and gene therapies, personalized medicines, high potency active pharmaceutical ingredients, and antibody-drug conjugates is further fueling market demand. However, challenges such as the need for serialization and a shortage of qualified professionals may hinder growth. Overall, the landscape is evolving, reflecting the industry's responsiveness to emerging therapeutic needs and technological advancements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmaceutical Contract Development and Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pharmaceutical Contract Development and Manufacturing Market Segments Analysis

Global Pharmaceutical Contract Development and Manufacturing Market is segmented by Service, End User and region. Based on Service, the market is segmented into Pharmaceutical Manufacturing Services, Drug Development Services, Biologics Manufacturing Services and Packaging Services. Based on End User, the market is segmented into Large Pharmaceutical Companies, Small and Mid-size Pharmaceutical Companies, Generic Pharmaceutical Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pharmaceutical Contract Development and Manufacturing Market

The Global Pharmaceutical Contract Development and Manufacturing market is experiencing growth due to the myriad benefits associated with outsourcing, particularly cost and time efficiencies. Companies in this sector are eager to capture greater shares of the outsourcing revenue by investing significantly in enhancing their infrastructure, workforce, and technological capabilities. This strategic focus on improving operational efficiency and resource allocation enables these firms to better meet the demands of their clients, facilitating a more streamlined and cost-effective production process. As a result, the market continues to expand, driven by the increasing reliance on specialized external partners for pharmaceutical development and manufacturing needs.

Restraints in the Global Pharmaceutical Contract Development and Manufacturing Market

A deficiency in process comprehension can lead to flawed product lines, subsequently undermining consumer trust and jeopardizing the relationships among developers, manufacturers, and distributors. This uncertainty can diminish the overall reliability of the Global Pharmaceutical Contract Development and Manufacturing market, as stakeholders may become hesitant to engage in collaborations due to concerns over quality assurance. As a result, the potential for product recalls and negative publicity looms larger, ultimately impacting profitability and sustainability in the industry. Therefore, enhancing process understanding is crucial to mitigate these risks and foster a more robust and trustworthy market environment.

Market Trends of the Global Pharmaceutical Contract Development and Manufacturing Market

The Global Pharmaceutical Contract Development and Manufacturing market is witnessing a significant trend driven by the escalating demand for specialized oncology treatments and advancements in drug development technology. As cancer incidence rises, there is a pronounced shift towards developing safe, effective, and highly potent New Chemical Entities (NCEs) that offer greater selectivity and improved dosing regimens. This growing interest in targeted therapies is prompting pharmaceutical companies to leverage contract services for efficient manufacturing solutions, enhancing their ability to bring innovative drugs to market swiftly. Consequently, the market is evolving with a focus on scalability, flexibility, and stringent quality compliance to meet these emerging needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Case Studies

Global Pharmaceutical Contract Development and Manufacturing Market Size by Service & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Manufacturing Services
  • API Manufacturing Services
  • FDF Manufacturing Services
• Drug Development Services
• Biologics Manufacturing Services
  • API Manufacturing Services
  • FDF Manufacturing Services
• Packaging Services

Global Pharmaceutical Contract Development and Manufacturing Market Size by End User & CAGR (2026-2033)

• Market Overview
• Large Pharmaceutical Companies
• Small and Mid-size Pharmaceutical Companies
• Generic Pharmaceutical Companies
• Others

Global Pharmaceutical Contract Development and Manufacturing Market Size & CAGR (2026-2033)

• North America (Service, End User)
  • US
  • Canada
• Europe (Service, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Cambrex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siegfried Holdings AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Diosynth Biotechnologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aenova Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuxi Biologics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma, Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetter Pharma International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almac Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fabbrica Italiana Sintetici S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fareva SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C.H. Boehringer Sohn AG & Co. KG.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Pharmova Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia Global, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Delpharm Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations